(2,2-二甲基-2,3-二氢-1-苯并呋喃-7-基)甲胺 | 868755-44-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: (2,2-二甲基-2,3-二氢-1-苯并呋喃-7-基)甲胺
• 英文名称: (2,2-Dimethyl-2,3-dihydro-1-benzofuran-7-YL)methylamine
• 英文别名: (2,2-dimethyl-3H-1-benzofuran-7-yl)methanamine
• CAS: 868755-44-6
• 化学式: C₁₁H₁₅NO
• 分子量: 177.24
• InChiKey: BQEPNISHAAOSFF-UHFFFAOYSA-N

物化性质

• 沸点：
  70 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  C
• 海关编码：
  2932999099

文献信息

• SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS
  申请人：Herdewijn Piet André Maurits Maria

  公开号：US20090318456A1

  公开（公告）日：2009-12-24

  Tri-substituted pteridines and tetra-substituted pteridines exhibit a significant and selective activity against certain types of viral infections, in particular they selectively inhibit the replication of the hepatitis C virus, and are useful for the prevention and treatment of such infections.

  三取代喹啉和四取代喹啉对某些类型的病毒感染表现出显著和选择性的活性，特别是它们选择性地抑制丙型肝炎病毒的复制，并可用于预防和治疗此类感染。
• SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS
  申请人：Herdewijn Piet Andre' Maurits Maria

  公开号：US20090253696A1

  公开（公告）日：2009-10-08

  This invention provides di-, tri- and tetra-substituted pyrido(3,2-d)pyrimidine derivatives with specific substituting patterns, their pharmaceutically acceptable salts, N-oxides, solvates, pro-drugs and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular being highly active antiviral agents. The invention also provides use of such derivatives in the treatment of viral infections and pathologic conditions associated therewith, including hepatitis C.

  这项发明提供了具有特定取代模式的二、三和四取代吡啶并[3,2-d]嘧啶衍生物，其药学上可接受的盐、N-氧化物、溶剂合物、前药和对映体，具有意外地理想的药理特性，特别是作为高活性抗病毒剂。该发明还提供了利用这些衍生物治疗病毒感染及相关病理状况，包括丙型肝炎的用途。
• COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES
  申请人：Swann Steven L.

  公开号：US20090258907A1

  公开（公告）日：2009-10-15

  Disclosed herein are compounds of formula (I) or pharmaceutical acceptable salts thereof, wherein X, R 1 , R 2 , R 3 , R 4 , L 1 , and m, are defined in the specification. Compositions comprising said compounds which can be useful for inhibiting Rho kinase (ROCK) and methods for using said compositions are also described.

  本文披露了公式(I)的化合物或其药物可接受的盐，其中X、R1、R2、R3、R4、L1和m在规范中定义。还描述了包含所述化合物的组合物，其可以用于抑制Rho激酶（ROCK），以及使用所述组合物的方法。
• 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS
  申请人：Gao Ling-Jie

  公开号：US20090285782A1

  公开（公告）日：2009-11-19

  This invention provides quinazoline derivatives represented by the structural formula: (I); wherein: R 2 is hydrogen, NR′R″, C 1-7 alkyl, arylC 1-7 alkyl or C 3-10 cycloalkyl; R 4 is amino, C 1-7 alkyl, C 2-7 alkenyl, C 3-10 cycloalkyl, C 3-10 cycloalkenyl, aryl, heterocyclic, arylalkyl, heterocyclic-substituted C 1-7 alkyl or C 3-10 cycloalkyl-C 1-7 alkyl; R 5 is hydrogen or C 1-7 alkyl, or R 5 and R 4 together with the nitrogen atom to which they are attached form a heterocyclic ring; Y is a single bond, C 1-7 alkylene, C 2-7 alkenylene or C 2-7 alkynylene; R 6 is halogen, heteroaryl or aryl; R′ and R″ are each independently hydrogen, C 1-7 alkyl-carbonyl or C 1-7 alkyl; provided that R 4 is not phenyl substituted with morpholino when R 2 is H and R 5 is H, and provided that when NR 4 R 5 is piperazinyl, said NR 4 R 5 is either non-substituted or substituted with methyl or acetyl; a pharmaceutically acceptable addition salt, a stereoisomer, a mono- or a di-N-oxide, a solvate or a pro-drug thereof, for the treatment of viral infections.

  该发明提供了由结构式(I)表示的喹唑啉衍生物；其中：R2是氢、NR′R″、C1-7烷基、芳基C1-7烷基或C3-10环烷基；R4是氨基、C1-7烷基、C2-7烯基、C3-10环烷基、C3-10环烯基、芳基、杂环、芳基烷基、杂环取代的C1-7烷基或C3-10环烷基-C1-7烷基；R5是氢或C1-7烷基，或者R5和R4与它们所连接的氮原子一起形成杂环环；Y是单键、C1-7烷基、C2-7烯基或C2-7炔基；R6是卤素、杂环芳基或芳基；R′和R″各自独立地是氢、C1-7烷基-羰基或C1-7烷基；前提是当R2为H且R5为H时，R4不是取代有吗啡啶基的苯基；当NR4R5是哌嗪基时，所述的NR4R5要么未取代，要么被甲基或乙酰基取代；其药学上可接受的加合物、立体异构体、单烯氮或双烯氮、溶剂化合物或前药，用于治疗病毒感染。
• 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS
  申请人：Gao Ling-Jie

  公开号：US20100143299A1

  公开（公告）日：2010-06-10

  This invention provides the treatment of viral infections with a 4,6-disubstituted or 2,4,6-trisubstituted quinazoline derivative represented by the structural formula [(I)] wherein: R 2 is selected from the group consisting of hydrogen, NR′R″ and C 1-7 alkyl; —A is selected from the group consisting of a bond, O, S(O) n , C 1-7 alkylene, C 2-7 alkenylene and C 2-7 alkynylene; R 4 is selected from the group consisting of C 1-7 alkyl, C 2-7 alkenyl, C 3-10 cycloalkyl, C 3-10 cycloalkenyl, aryl, heterocyclic, arylalkyl, heterocyclic-substituted alkyl and cycloalkyl-alkyl; —Y is selected from the group consisting of a single bond, C 1-7 alkylene, C 2-7 alkenylene, and C 2-7 alkynylene; n is 0, 1 or 2; and R 6 is selected from the group consisting of halogen, heteroaryl and aryl; a pharmaceutically acceptable addition salt, a stereoisomer, a mono- or a di-Λ/-oxide, a solvate or a pro-drug thereof.

  本发明提供了一种使用4,6-二取代或2,4,6-三取代喹唑啉衍生物的治疗病毒感染的方法，其结构式表示为[(I)]，其中：R2选自氢、NR′R″和C1-7烷基的组；—A选自键、O、S(O)n、C1-7烷基、C2-7烯基和C2-7炔基的组；R4选自C1-7烷基、C2-7烯基、C3-10环烷基、C3-10环烯基、芳基、杂环、芳基烷基、杂环取代烷基和环烷基-烷基的组；—Y选自单键、C1-7烷基、C2-7烯基和C2-7炔基的组；n为0、1或2；R6选自卤素、杂芳基和芳基的组；以及其药学上可接受的加合物盐、立体异构体、单-或双-Λ/-氧化物、溶剂化合物或前药。